הרצאה בכנס האנדוקריני הישראלי – IES, במרץ 2017 – לתוכנית המלאה של הכנס – לחץ כאן.
הצגת מחקר בנושא:
Anti-Mullerian Hormone serum levels remain stable under cross-sex hormone therapy of transgender men
Iris Yaish1 , Iris Yaish1 , Gustavo Melinger2 , Yael Sofer1 , Nechama Golani1 , Marianna Yaron1 , Dana Zaid1 , Foad Azem2 , Naftali Stern1 , Yona Greenman1 1 Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Israel 2 Lis Maternity Hospital, Tel Aviv-Sourasky Medical Center, Israel
Background: Although successful pregnancies carried by transgender men have been reported, long-term effects of testosterone therapy on fertility remain unknown.
Aims: To study markers of ovarian reserve during testosterone therapy
Methods: Prospective open-label study of transgender men prior and during treatment with IM Testoviron Depot 250 mg q3 weeks. Sampling was conducted in the follicular phase at baseline and 10 days following the testosterone injection three and 12 months subsequently.
Main outcome measures: AMH serum levels; endometrial thickness and antral follicular count determined by pelvic US.
Results: Thirty five subjects (mean age 24±5.9 y) were included. Preliminary results of twenty two patients with at least one follow up visit are reported.
AMH levels were within the normal range (5.8±2.9 ng/ml) and did not change significantly after three (5.3±2.4 ng/ml, N=22) and 12 months of treatment (4±2.2 ng/ml, N=8). As expected, testosterone levels increased (0.57 ± 0.7, 6 ±3.2 ,6.6 ±2.8 ng/ml; p0.0001) and estradiol levels decreased (187±184 , 57±15, 54.8 pg/ml; p=0.012) after three and 12 months respectively. There was a modest but significant decrease in
LH levels (7.7±5, 4.2±3.4, 3.9 ± 2.8 mIU/ml, p=0.022), but FSH levels (4.1±1.7, 4.4±2.2, 4.7±1.8 mIU/ml), as well as endometrial thickness (7.2±3.9, 5.3±1.2, 5±3.3 mm) remained unchanged. In all but two studies, multiple ovarian small follicles were detected by pelvic sonography.
Conclusion: AMH levels remain stable during short term testosterone treatment. Further, there is no suppression of the hypothalamo-pituitary-gonadal axis and ovarian folliculogenesis is maintained. Longer follow up is needed for assessment of testosterone effects on fertility potential.
